Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration

Cancer Letters

Volumn 294, Issue 1, 2010, Pages 118-124

  Chan, Kin Tak ^a   Meng, Fan Yan ^a   Li, Qian ^a   Ho, Cheong Yip ^a   Lam, Tsz Shan ^a   To, Yu ^a   Lee, Wai Him ^a   Li, Miao ^a   Chu, Kee Hung ^a   Toh, Melvin ^a  

^a Department of Technology and Product Development   (China)

Author keywords

BEL 7402; C Raf; Cucurbitacin B; Hepatocellular carcinoma

Indexed keywords

CUCURBITACIN; CUCURBITACIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-RAF; S PHASE; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES;

EID: 77953021503     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.029     Document Type: Article

References (47)

1. Avila M.A., Berasain C., Sangro B., Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006, 25(27):3866-3884.
2. Martin J., Dufour J.F. Tumor suppressor and hepatocellular carcinoma. World J. Gastroenterol. 2008, 14(11):1720-1733.
3. Zhang M., Zhang H., Sun C., Shan X., Yang X., Li-Ling J., Deng Y. Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother. Pharmacol. 2009, 63(4):635-642.
4. Gusani N.J., Jiang Y., Kimchi E.T., Staveley-O'Carroll K.F., Cheng H., Ajani J.A. New pharmacological developments in the treatment of hepatocellular cancer. Drugs 2009, 69(18):2533-2540.
5. Daniels D., Grytdal S., Wasley A. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ. 2009, 58(3):1-27.
6. Chen J.C., Chiu M.H., Nie R.L., Cordell G.A., Qiu S.X. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat. Prod. Rep. 2005, 22(3):386-399.
7. Chambliss O.L., Jones C.M. Cucurbitacins: specific insect attractants in Cucurbitaceae. Science 1996, 153(3742):1392-1393.
8. Jayaprakasam B., Seeram N.P., Nair M.G. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett. 2003, 189(1):11-16.
9. Agil A., Miro M., Jimenez J., Aneiros J., Caracuel M.D., Garcia-Granados A., Navarro M.C. Isolation of anti-hepatotoxic principle from the juice of Ecballium elaterium. Planta Med. 1999, 65(7):673-675.
10. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63(3):1270-1279.
11. Duncan K.L., Duncan M.D., Alley M.C., Sausville E.A. Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem. Pharmacol. 1996, 52(10):1553-1560.
12. Meng D., Qiang S., Lou L., Zhao W. Cytotoxic cucurbitane-type triterpenoids from Elaeocarpus hainanensis. Planta Med. 2008, 74(14):1741-1744.
13. Peter R.R., Farias M.R., Ribeiro-do-Valle R.M. Anti-inflammatory and analgesic effects of cucurbitacins from Wibrandia ebracteata. Planta Med. 1997, 63(6):525-528.
14. Frei B., Heinrich M., Herrmann D., Orjala J.E., Schmitt J., Sticher O. Phytochemical and biological investigation of Begonia heracleifolia. Planta Med. 1998, 64(4):385-386.
15. Wakimoto N., Yin D., O'Kelly J., Haritunians T., Karlan B., Said J., Xing H., Koeffler H.P. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci. 2008, 99(9):1793-1797.
16. Liu T., Zhang M., Zhang H., Sun C., Deng Y. Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 2008, 265(10):1225-1232.
17. Thoennissen N.H., Iwanski G.B., Doan N.B., Okamoto R., Lin P., Abbassi S., Song J.H., Yin D., Toh M., Xie W.D., Said J.W., Koeffler H.P. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009, 69(14):5876-5884.
18. Aggarwal B.B., Sethi G., S Ahn K., Sandur S.K., Pandey M.K., Kunnumakkara A.B., Sung B., Ichikawa H. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. NY Acad. Sci. 2006, 1091:151-169.
19. Liu T., Zhang M., Zhang H., Sun C., Yang X., Deng Y., Ji W. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur. J. Pharmacol. 2008, 587(1-3):78-84.
20. Chan K.T., Li K., Liu S.L., Chu K.H., Toh M., Xie W.D. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett. 2009, (August). (Epub. ahead of print).
21. Yasuda S., Yogosawa S., Izutani Y., Nakamura Y., Watanabe H., Sakai T. Cucurbitacin B induces G(2) arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol. Nutr. Food Res. 2009, (November). (Epub. ahead of print).
22. Das T., Patra F., Mukherjee B. Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat. Cancer Chemother. Pharmacol. 2009, (June). (Epub. ahead of print).
23. Aviel-Ronen S., Blackhall F.H., Shepherd F.A., Tsao M.S. K-ras mutations in non-small lung carcinoma: a review. Clin. Lung Cancer. 2006, 8(1):30-38.
24. Akagi K., Uchibori R., Yamaguchi K., Kurosawa K., Tanaka Y., Kozu T. Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem. Biophys. Res. Commun. 2007, 352(3):728-732.
25. Deramaudt T., Rustgi A.K. Mutant KRAS in the initiation of pancreatic cancer. Biochim. Biophys. Acta 2005, 1756(2):97-101.
26. Chen R., Zhu D., Ye X., Shen D., Lu R. Establishment of three human liver carcinoma cell lines and some of their biological characteristics in vitro. Sci. Sin. 1980, 23(2):236-247.
27. Haritunians T., Gueller S., Zhang L., Badr R., Yin D., Zing H., Fung M.C., Koeffler H.P. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alternations in myeloid leukemia cells. Leuk. Res. 2008, 32(9):1366-1373.
28. Yin D., Wakimoto N., Xing H., Lu D., Huynh T., Wang X., Black K.L., Koeffler H.P. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int. J. Cancer 2008, 123(6):1364-1375.
29. Peng S.H., Yang J.F., Xie P.P., Deng H., Feng D.Y. Expression of cyclins in hepatocellular carcinoma and its correlation to tumor cell apoptosis. Ai Zheng 2005, 24(6):695-698.
30. Cooper W.A., Kohonen-Corish M.R., McCaughan B., Kennedy C., Sutherland R.L., Lee C.S. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009, 55(1):28-36.
31. Han Y.H., Kim S.H., Kim S.Z., Park W.H. Antimycin A as a mitochondria damage agent induces an S phase arrest of the cell cycle in HeLa cells. Life Sci. 2008, 83(9-10):346-355.
32. Parekh P., Rao K.V. Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during dietheylnitrosamine-induced progressive liver carcinogenesis. Cell Biol. Int. 2007, 31(1):35-43.
33. Chen T., Wong Y.S. Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation. J. Agric. Food Chem. 2008, 56(22):10574-10581.
34. Deng J., Grande F., Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drugs Targets 2007, 7(1):91-107.
35. Chau M.N., Banerjee P.P. Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors. Biochem. Biophys. Res. Commun. 2008, 377(2):627-631.
36. Costantino L., Barlocco D. STAT 3 as a target for cancer drug discovery. Curr. Med. Chem. 2008, 15(9):834-843.
37. Sun C., Zhang M., Shan X., Zhou X., Yang J., Wang Y., Li-Ling J., Deng Y. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J. Cancer Res. Clin. Oncol. 2009, (October). (Epub. ahead of print).
38. Lui V.W., Yau D.M., Wong E.Y., Ng Y.K., Lau C.P., Ho Y., Chan J.P., Hong B., Ho K., Cheung C.S., Tsang C.M., Tsao S.W., Chan A.T. Cucurbitacin I elicits Anoikis-sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 2009, (October). (Epub. ahead of print).
39. Tannin-Spitz T., Grossman S., Dovrat S., Gottlieb H.E., Bergman M. Growth inhibitory activity of cucurbitacin glucoside isolated from Citrullus colocynthis on human breast cancer cells. Biochem. Pharmacol. 2007, 73(1):56-67.
40. Borlak J., Jenke H.S. Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation. Mol. Cancer Res. 2008, 6(8):1326-1336.
41. Suzuki H., Fujita H., Mullauer L., Kuzumaki N., Konaka S., Togashi Y., Takeichi N., Kawamukai Y., Uchino J. Increased expression of c-jun gene during spontaneous hepatocarcinogenesis in LEC rats. Cancer Lett. 1990, 53(2-3):205-212.
42. Lin K.L., Su J.C., Chien C.M., Tseng C.H., Chen Y.L., Chang L.S., Lin S.R. Naphtho[1,2-b]furan-4,5-dione induces apoptosis and S-phase arrest of MDA-MB-231 cells through JNK and ERK signaling activation. Toxicol. In Vitro 2009, (September). (Epub. ahead of print).
43. Wei S.Y., Li M., Tang S.A., Sun W., Xu B., Cui J.R., Lin W.H. Induction of apoptosis accompanying with G(1) phase arrest and microtubule disassembly in human hepatoma cells by jaspolide B, a new isomalabaricane-type triterpene. Cancer Lett. 2008, (January). (Epub. ahead of print).
44. Steelman L.S., Abrams S.L., Whelan J., Bertand F.E., Ludwig D.E., Basecke J., Stivala F., Milella M., Tafuri A., Lunghi P., Bonati A., Martelli A.M., McCubrey J.A. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22(4):686-707.
45. McCubery J.A., Steelman L.S., Abrams S.L., Bertand F.E., Ludwig D.E., Basecke J., Libra M., Stivala F., Milella M., Tafuri A., Lunghi P., Bonati A., Martelli A.M. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22(4):708-722.
46. Liu L., Xie Y., Lou L. PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation. Eur. J. Cell. Biol. 2006, 85(5):367-374.
47. Wen-Sheng W. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Cancer Lett. 2006, 239(1):27-35.